Thermo Fisher Scientific
Se presenta el 11 de noviembre
Representante Thermo Fisher Scientific
Jordi Petriz received his BSc degree in Biochemistry and Animal Biology from the University of Barcelona. He then pursued his PhD at Barcelona after acceptance at the Cryobiology and Cell Therapy Department, Cancer Research Institute. In 1998 he obtained his PhD degree in Physiology and Immunology specializing in functional-based mechanisms on multidrug resistance against anticancer agents. The cytomic functional approach was used to account for multidrug transporters and drug resistance profiling in highly refractory cancer cells. As a postdoctoral fellow he applied new cytomic approaches to address questions on whole blood counting of CD34+ progenitor cells. Since 2000, he joined the Subcommittee on Quality Assessment of Hematopoietic Stem Cell Grafts (established by the European Group for Bone Marrow Transplantation). Since then he has become a Principal Investigator at the IJC. Jordi Petriz has authored or co-authored nearly 100 research contributions; some in high impact Journals including Nature Medicine and Leukemia. His current work focuses on linking stemness with ABC transporters. He is studying several genes involved in different aspects of stem cell activation, including some that encode for multidrug resistance transporters, and others that regulate self-renewal and differentiation. He has been the President of the Iberian Society for Cytometry (SIC), Councilor at the European Society for Clinical Cell Analysis (ESCCA) Executive Board, and current Corse Committee Member at the Clinical Cytometry Education Network (CCEN). He finally joined the IJC at the beginning of 2015.